Candriam S.C.A. Cuts Stock Position in IDEAYA Biosciences, Inc. $IDYA

Candriam S.C.A. cut its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 2.5% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 914,400 shares of the company’s stock after selling 23,777 shares during the period. Candriam S.C.A. owned about 1.04% of IDEAYA Biosciences worth $19,222,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. PNC Financial Services Group Inc. increased its stake in shares of IDEAYA Biosciences by 180.2% during the first quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company’s stock worth $39,000 after purchasing an additional 1,546 shares in the last quarter. CWM LLC lifted its stake in IDEAYA Biosciences by 325.7% in the 1st quarter. CWM LLC now owns 2,371 shares of the company’s stock valued at $39,000 after buying an additional 1,814 shares in the last quarter. Signaturefd LLC lifted its stake in IDEAYA Biosciences by 374.8% in the 1st quarter. Signaturefd LLC now owns 2,877 shares of the company’s stock valued at $47,000 after buying an additional 2,271 shares in the last quarter. Parallel Advisors LLC boosted its holdings in IDEAYA Biosciences by 72.4% in the 2nd quarter. Parallel Advisors LLC now owns 3,260 shares of the company’s stock worth $69,000 after buying an additional 1,369 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in IDEAYA Biosciences by 9.1% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 7,483 shares of the company’s stock worth $123,000 after buying an additional 627 shares in the last quarter. 98.29% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

IDYA has been the topic of several research reports. Oppenheimer set a $36.00 target price on IDEAYA Biosciences and gave the company an “outperform” rating in a research report on Monday, September 8th. TD Cowen assumed coverage on IDEAYA Biosciences in a report on Tuesday, July 22nd. They issued a “buy” rating on the stock. New Street Research set a $30.00 target price on shares of IDEAYA Biosciences in a research note on Tuesday, October 21st. Cantor Fitzgerald reiterated an “overweight” rating on shares of IDEAYA Biosciences in a research report on Tuesday, September 9th. Finally, Citizens Jmp assumed coverage on shares of IDEAYA Biosciences in a research note on Thursday, September 4th. They issued a “mkt outperform” rating and a $41.00 price target on the stock. Fourteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $45.50.

IDEAYA Biosciences Stock Down 0.4%

Shares of IDYA opened at $31.82 on Friday. IDEAYA Biosciences, Inc. has a 52-week low of $13.45 and a 52-week high of $33.64. The stock has a fifty day simple moving average of $28.01 and a two-hundred day simple moving average of $24.07. The company has a market capitalization of $2.79 billion, a PE ratio of -17.11 and a beta of 0.14.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $1.33 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $1.45. The firm had revenue of $207.83 million during the quarter, compared to analysts’ expectations of $59.98 million. As a group, equities analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current fiscal year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.